dCBP-1

SKU: orb1298145

Description

dCBP-1 is a small molecule that selectively degrades the p300/CBP proteins by recruiting the CRBN E3 ubiquitin ligase. This targeted degradation has demonstrated potent anti-proliferative effects in multiple myeloma cell lines in vitro, supporting its use as a chemical probe in oncology and epigenetics research.

Research Area

Epigenetics & Chromatin, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 2484739-25-3
• MW: 1028.11
• Purity: 99.12% (May vary between batches)
• Formula: C₅₁H₆₃F₂N₁₁O₁₀
• SMILES: C(NC)(=O)N1CC=2C(=NN(C2CC1)C3CCN(C(CCOCCOCCOCCOCCNC=4C=C5C(=CC4)C(=O)N(C5=O)C6C(=O)NC(=O)CC6)=O)CC3)N7C=8C(=CC(=C(C(F)F)C8)C9=CN(C)N=C9)CCC7
• Target: PROTACs,Epigenetic Reader Domain
• Solubility: DMSO:50 mg/mL (48.63 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (1.95 mM)

Bioactivity

• In Vitro:
  Treatment of the human haploid cell line HAP1 for 6 h with dCBP-1 revealed almost complete loss of both CBP and p300 between 10 and 1,000 nM doses. A time course analysis with 250 nM dCBP-1 revealed almost complete degradation of p300/CBP within an hour of treatment. dCBP-1 was also able to induce near-complete p300/CBP degradation across other multiple myeloma cell lines tested, including MM1R, KMS-12-BM, and KMS34.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cereblon, cell, CBP/p300, CBP, CRBN, degrader, Epigenetic Reader Domain, EpigeneticReaderDomain, dCBP 1, dCBP1, dCBP-1, heterobifunctional, Inhibitor, inhibit, myeloma, MYC, multiple, p300, PROTACs

Compound Identifiers

PubChem CID

154690309